- Home
- IINN vs BOLD Comparison
IINN vs BOLD Comparison
Compare IINN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IINN | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 28.4M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | IINN | BOLD |
|---|---|---|
| Price | $0.79 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 189.7K | 125.9K |
| Earning Date | 03-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $289,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9,715.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $1.00 |
| 52 Week High | $1.65 | $2.54 |
Technical Indicators
Market Signals| Indicator | IINN | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 46.13 |
| Support Level | $0.75 | $1.19 |
| Resistance Level | $0.91 | $1.31 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 14.44 | 12.50 |
Price Performance
Historical ComparisonAbout IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.